BTX-1188

N/A

Report date: 2023/12/14 18:18:29

NME

Base Information

Drug NameBTX-1188

Drug Alias NameBTX-1188BTX-508

ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue

Mechanisms of ActionEukaryotic peptide chain release factor GTP-binding subunit ERF3A inhibitorsCasein kinase I isoform alpha inhibitorsDNA-binding protein Ikaros inhibitors

TargetsEukaryotic peptide chain release factor GTP-binding subunit ERF3ACasein kinase I isoform alphaDNA-binding protein Ikaros

Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma, Non-Hodgkin +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesThe Hebrew University Of Jerusalem

China Registration ClassN/A

Develop Information

Active CompaniesBiotheryx Inc

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsSolid tumoursLymphoma, Non-HodgkinLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A